Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Matthew Gillmor
Period: Reporting periods mapped to calendar 2024 Q4 – 2026 Q3 (8 quarters).
- Questions
- 21on tracked calls
- Challenge rate
- 0%none of 21 questions
- Companies
- 4questioned at least once
- Reporting periods
- 8with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 21 of 21 questions from 4 companies
UHSUniversal Health Services11 questions · 6 reporting periods · 0 of 11 challenging
Calendar 2026 Q2
If this program is renewed for fiscal 26, would the sizing of the 2026 program be about the same
Show response
Filton was clear that no 2026 Florida benefit is booked or guided, and that other state programs are not expected to be material.
how we should think about the ramp of facility in San Antonio once it gets the CMS certification back
Show response
No timeline or ramp shape offered; Filton pointed to community demand as the reason he expects a fast ramp when it comes.
Calendar 2026 Q1
on professional fees, any trend updates and what are you doing to alleviate pressure, particularly in radiology?
Show response
Filton said professional fees tracking within guided high-single-digit range. Addressing hospital-based physician pressure through competitive RFPs and reducing expensive locums usage. Daily operational focus keeping fees manageable.
it seemed like rate outperformed even excluding the DPP. What drove the stronger price in the quarter, and why do you expect moderation for the rest of the year?
Show response
Filton said lower flu volume mechanically increased acuity mix (flu patients are lower-acuity). Also saw strong higher-acuity service line growth in cardiology, orthopedics, neurology. Expects more balanced contribution between rate and volume as year progresses.
Calendar 2025 Q4
For the programs that are not yet approved like Florida and I think maybe California, do you have any sense for where those approval processes stand with CMS?
Show response
Filton said Florida DPP ($45-50M) still expected approved but taking longer than anticipated; not in guidance. California DPP faces more hurdles and may need significant modification. Rural health program could provide modest benefit but relatively few UHS facilities carry rural designation.
Calendar 2025 Q3
is there any geographic variation to call out to highlight, particularly in some of your larger markets like Las Vegas?
Show response
Filton said Vegas performance consistent with overall portfolio despite tourist volume declines. Unemployment stable in market currently. Watching for potential ripple effects on economy but not seeing them yet. No other significant geographic variation.
Is there a way for us to think about how that breaks down the net benefit between acute and behavioral?
Show response
Filton said Nevada DPP increase is predominantly acute. Did not have Florida breakdown available during the call.
Calendar 2025 Q2
Are you able to quantify what that impact would be? Or just give us some sense for the drag on the same-store?
Show response
Filton estimated West Henderson cannibalization at 50-60 basis points on same-facility adjusted admissions and a similar impact on revenues based on ZIP code analysis.
I wanted to see if there was anything to report with respect to professional fees and physician expenses
Show response
Filton said physician fees still tracking at ~5% growth guidance. New pressure from radiologists seeking subsidies after prior waves from ER doctors and anesthesiologists, but still within the guided range.
Calendar 2025 Q1
Any areas of particular outperformance to call out and sort of how you're feeling about the sustainability of that?
Show response
Filton confirmed $63M premium pay in Q1, consistent. Expense controls driven by labor stabilization, decelerated wage inflation, and active productivity management.
are you still expecting $997 million from the last disclosure? Or is that number changed at all?
Show response
Filton confirmed the $997M 2025 Medicaid supplemental payment expectation remains materially unchanged.
HCAHCA Healthcare7 questions · 7 reporting periods · 0 of 7 challenging
Calendar 2026 Q2
You had mentioned that 3 divisions represented 50% of the impact Can you give some context
Show response
Hazen named all three divisions explicitly and characterized the magnitude of the adjusted admission decline in those markets.
Calendar 2026 Q1
give us an update in terms of how things are playing out and if there's any signs that those markets are improving
Show response
Sam explained demand exceeds expectations but labor costs are elevated due to workforce deficit in Western NC. Bottom line slightly behind expectations.
Calendar 2025 Q4
Can you give us a sense for how the exchange reforms and the subsidy expirations will impact the volume outlook?
Show response
Mike confirmed exchange drag absorbed within 2-3% volume guide. Of those losing coverage, 15-20% to ESI, remainder uninsured with ~30% utilization decline. Exchange population uses ER more heavily than traditional commercial.
Calendar 2025 Q3
There was a little bit of an improvement this quarter versus last quarter. Sam just mentioned some of the seasonal dynamics. Can you give us a sense for some of the service lines
Show response
Sam detailed outpatient strength in general surgery and urology, inpatient strength in neurosciences, orthopedics, and cardiac. Gynecology slightly down outpatient, neurosurgery modestly down inpatient.
Calendar 2025 Q2
there was a comment about a handful of markets that were underperforming. Can you give us some sense for the drivers of that underperformance
Show response
Sam noted 2 of 15 US divisions underperforming: one from competitive dynamics dislocating business, another from service mix change in Q2 expected to recover in H2. Declined to name specific markets.
Calendar 2025 Q1
do you see how system competitors behaving any differently in terms of their CapEx priorities or investments? Maybe that creates an opportunity for HCA
Show response
Sam noted no competitive behavior changes yet, but NIH funding pressure on academic centers could create opportunity. HCA's scale and diversification provide advantage over local competitors.
Calendar 2024 Q4
I want to see if there's any commentary on the California wildfires. And I know you've got a couple of facilities in the L.A. area, but any impact there to call out
Show response
Sam confirmed no impact from California wildfires. Ventura County facility was on alert but Palisades Fire did not reach their locations.
UNHUnitedHealth Group Incorporated2 questions · 2 reporting periods · 0 of 2 challenging
Calendar 2026 Q3
I am just hoping you could give us a sense for how you would like to see those programs evolve over the next few years
Show response
Tim Noel called IDR awards at 10, 11 times Medicare rates excessive, and Bobby Hunter backed thoughtful Medicare Advantage modernization with program stability.
Calendar 2025 Q2
Can you get some detail on nature of those settlements? Are those mostly tied to value-based care contracts and Optum Health?
Show response
Rex said settlements span businesses including questionable receivables and disputed items dating back a year or more. Breakdown: about $500 million in Optum Health, $850 million in UHC, couple hundred million in Optum Insight, under $100 million in Optum Rx, plus about $100 million in corporate items.
HUMHumana1 question · 1 reporting period · 0 of 1 challenging
Calendar 2025 Q4
Can you just remind us the proportion of MA members that are capitated?
Show response
George confirmed roughly one-third split: full risk, other value-based, and non-value-based/basic pay-for-performance. New member influx temporarily lowers paneled percentage at start of year, builds back up. Value-based partners wanting to expand significantly.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| UHS Universal Health Services | 11 | 0%none of 11 questions |
| HCA HCA Healthcare | 7 | 0%none of 7 questions |
| UNH UnitedHealth Group Incorporated | 2 | —Rate withheld: fewer than 3 questions |
| HUM Humana | 1 | —Rate withheld: fewer than 3 questions |
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2024 Q4 | 1 | 0%none of 1 question | 1 |
| 2025 Q1 | 3 | 0%none of 3 questions | 2 |
| 2025 Q2 | 4 | 0%none of 4 questions | 3 |
| 2025 Q3 | 3 | 0%none of 3 questions | 2 |
| 2025 Q4 | 3 | 0%none of 3 questions | 3 |
| 2026 Q1 | 3 | 0%none of 3 questions | 2 |
| 2026 Q2 | 3 | 0%none of 3 questions | 2 |
| 2026 Q3 | 1 | 0%none of 1 question | 1 |
- 2024 Q41 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q13 questions · challenge rate 0% (none of 3 questions) · 2 companies
- 2025 Q24 questions · challenge rate 0% (none of 4 questions) · 3 companies
- 2025 Q33 questions · challenge rate 0% (none of 3 questions) · 2 companies
- 2025 Q43 questions · challenge rate 0% (none of 3 questions) · 3 companies
- 2026 Q13 questions · challenge rate 0% (none of 3 questions) · 2 companies
- 2026 Q23 questions · challenge rate 0% (none of 3 questions) · 2 companies
- 2026 Q31 question · challenge rate 0% (none of 1 question) · 1 company
Topics
Topics tagged on this analyst’s questions.
- Regulation Policy8
- Demand6
- Cost Pressure5
- Competitive Dynamics4
- Geographic Expansion2
- Guidance Reliability2
- Labor Market2
- Margin2
- Revenue Growth2
- Macroeconomic2
Show all 12 topics
- Capex Investment1
- Pricing1